Chronic Respiratory Disease Drug Development Pipeline Review, 2018
- Pages: 361
- Published: November 2018
- Report Code: GBIHC050IDB
This report provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
Asthma is a chronic disease involving the airways in the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, being overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. There are 275 products in development for this indication.
COPD is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs, leading to shortness of breath and blocked airflow to the lungs. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over time, increasing complications. The main risk factor is smoking. Exposure to chemicals and air pollution also contribute in the development of COPD. There are 187 products in development for this indication.
IPF is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. There are 136 products in development for this indication.
Molecular targets in development for chronic respiratory diseases include phosphodiesterases, adrenergic receptors, interleukins and chemokine receptors. Companies operating in this pipeline space include AstraZeneca, GlaxoSmithKline and Galapagos.
Scope
– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Companies mentioned
4D Pharma PLC
AbbVie Inc
Accolade Pharmaceuticals LLC
Ache Laboratorios Farmaceuticos SA
AdAlta Ltd
Advanced Inhalation Therapies (AIT) Ltd
Aeolus Pharmaceuticals Inc
AlgiPharma AS
ALK-Abello AS
Allergan Plc
Allergopharma GmbH & Co KG
Allinaire Therapeutics LLC
Almirall SA
Amgen Inc
Amphastar Pharmaceuticals Inc
Amplia Therapeutics Ltd
AnaMar AB
AnaptysBio Inc
AnGes Inc
Angiocrine Bioscience Inc
Antisense Therapeutics Ltd
Apollo Endosurgery Inc
Aridis Pharmaceuticals Inc
Asahi Kasei Corp
ASIT Biotech SA
Aslan Pharmaceuticals Pte Ltd
Aurigene Discovery Technologies Ltd
AusBio Ltd
BerGenBio ASA
Biocon Ltd
Biogen Inc
BiosanaPharma BV
BioStem Technologies Inc
Biotec Pharmacon ASA
BreStem Therapeutics Inc
Bristol-Myers Squibb Co
C4X Discovery Holdings PLC
Celdara Medical LLC
Celgene Corp
Certa Therapeutics Pty Ltd
China Resources Pharmaceutical Group Ltd
Chronic Obstructive Pulmonary Disease (COPD)
Cipla Ltd
Circassia Pharmaceuticals Plc
Compugen Ltd
Crossject SA
CrystalGenomics Inc
CSPC Pharmaceutical Group Limited
Cumberland Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Denceptor Therapeutics Ltd
Denovo Biopharma LLC
Diffusion Pharmaceuticals Inc
Domainex Ltd
Energenesis Biomedical Co Ltd
Errant Gene Therapeutics LLC
Evaxion Biotech ApS
FibroGen Inc
FibroStatin SL
FLX Bio Inc
Fountain Biopharma Inc
Galecto Biotech AB
Genentech Inc
GeneScience Pharmaceuticals Co Ltd
GenKyoTex SA
Gilead Sciences Inc
Global Blood Therapeutics Inc
Gossamer Bio Inc
Grifols SA
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Humanigen Inc
Hydra Biosciences Inc
iBio Inc
iCo Therapeutics Inc
Idiopathic Pulmonary Fibrosis
Idorsia Pharmaceutical Ltd
InKemia IUCT Group SA
InMed Pharmaceuticals Inc
Insmed Inc
Inspyr Therapeutics Inc
Inventiva
Isarna Therapeutics GmbH
JHL Biotech Inc
Johnson & Johnson
Kadmon Corp LLC
Knopp Biosciences LLC
Kyorin Pharmaceutical Co Ltd
Laboratorios LETI SL
Lead Discovery Center GmbH
LG Chem Ltd
LifeMax Laboratories Inc
Longevity Biotech Inc
Lung Therapeutics Inc
Merck & Co Inc
Mereo Biopharma Group Plc
Meridigen Biotech Co Ltd
Miragen Therapeutics Inc
Mission Therapeutics Ltd
Mitsubishi Tanabe Pharma Corp
Moerae Matrix Inc
Mycenax Biotech Inc
NAL Pharmaceuticals Ltd
NeoPharm Co Ltd
Novo Nordisk AS
Nuevolution AB
Nuformix Plc
Octapharma AG
OliX Pharmaceuticals Inc
Omeros Corp
OncBioMune Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Onspira Therapeutics Inc
Orbis Biosciences Inc
Oxagen Ltd
Paradigm Biopharmaceuticals Ltd
Paragen Bio Pty Ltd
PharmaLundensis AB
Pieris Pharmaceuticals Inc
Pliant Therapeutics Inc
Progenra Inc
Prommune Inc
Pulmagen Therapeutics LLP
Pulmokine Inc
Pulmotect Inc
Quark Pharmaceuticals Inc
Qurient Co Ltd
Redx Pharma Plc
Reliance Life Sciences Pvt Ltd
Resolys Bio Inc
Revalesio Corp
ReveraGen BioPharma Inc
Reviva Pharmaceuticals Inc
rEVO Biologics Inc
Rhizen Pharmaceuticals SA
Sam-A Pharm Co Ltd
Samumed LLC
SATT North SAS
Shionogi & Co Ltd
Sorrento Therapeutics Inc
Swecure AB
Synairgen Plc
Synermore Biologics Co Ltd
Synovo GmbH
Syntrix Biosystems Inc
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Telocyte LLC
Teva Pharmaceutical Industries Ltd
The Geneva Biotech Center SA
United BioPharma Inc
Unizyme Laboratories AS
Vascular BioSciences
Vectura Group Plc
Vicore Pharma AB
WhanIn Pharmaceutical Co Ltd
Xencor Inc
X-Rx Inc
Yuhan Corp
Yungjin Pharm Co Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.